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ABSTRACT
Background. Breast cancer is increasingly considered a
heterogeneous disease. The aim of this study was to assess
the differences between histological and receptor-based
subtypes in breast-conserving surgery and pathological
complete response (pCR) after neoadjuvant chemotherapy.
Method. A consecutive series of 254 patients with oper-
able breast cancer treated with neoadjuvant chemotherapy
was analyzed. Tumors were classiﬁed according to their
receptor status in estrogen receptor (ER)-positive tumors
(HER2-negative), triple-negative tumors, and HER2-posi-
tive tumors. The type of surgery feasible prior to
neoadjuvant chemotherapy was compared with the actual
surgery performed.
Results. The overall increase in breast-conserving surgery
was 37% (73 of 198). In patients with ductal and lobular
carcinomas this increase was 41% (63 of 152, 95% conﬁ-
dence interval [95% CI] 0.34–0.49) and 20% (7 of 35, 95%
CI 0.10–0.36), respectively (P = 0.02). Half of the patients
with lobular carcinoma had to undergo a secondary mas-
tectomy because of incomplete resection margins. In ER-
positive, triple-negative and HER2-positive tumors, the
increase in breast-conserving surgery was 39% (42 of 109,
95% CI 0.30–0.48), 24% (11 of 45, 95% CI 0.14–0.38),
and 45% (20 of 44, 95% CI 0.32–0.60) (P = 0.11). The
pCR rate in ductal and lobular carcinomas was 12% (23 of
195) and 2% (1 of 42), respectively (P = 0.09). In ER-
positive, triple-negative and HER2-positive tumors the
pCR rates were 2% (3 of 138), 28% (16 of 57), and 18%
(10 of 56), respectively. Multivariate analysis showed that
the receptor-based subtype was the only signiﬁcant pre-
dictor of pCR (P = 0.004).
Conclusion. In lobular tumors the beneﬁt with regard to
breast-conserving surgery of neoadjuvant chemotherapy is
questionable. Although in ER-positive tumors the pCR rate
is low, the increase in breast-conserving surgery was
remarkable in ductal ER-positive tumors.
Neoadjuvant chemotherapy is the standard of care in
patients with locally advanced breast cancer and is
increasingly being used in the treatment of patients with
large operable breast cancer or proven lymph node
metastases. In theory, early eradication of micrometastases
would prevent the outgrowth of distant metastases and
herewith improve survival. However, an overall survival
beneﬁt for neoadjuvant chemotherapy compared with
adjuvant chemotherapy has yet to be proven.
1 The use of
neoadjuvant chemotherapy in operable breast cancer has
other advantages. Firstly, downstaging of the tumor load
increases the rate of breast-conserving surgery.
2 Secondly,
neoadjuvant chemotherapy creates the opportunity to
assess in vivo the tumor response without requiring long-
term follow-up since pathological complete remission of
the primary tumor is associated with an improved
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1,3 Furthermore, response monitoring during the
chemotherapy course may potentially create the ability to
adjust the chemotherapy regimen to the response of the
primary tumor at an early stage.
4 Tailored treatment could
be a major gain of neoadjuvant treatment and might ulti-
mately lead to a survival beneﬁt. However, the ﬁrst trial
addressing this question, the Gepartrio trial, showed no
beneﬁt of switching nonresponders.
5
Neoadjuvant chemotherapy offers the unique opportu-
nity to assess the sensitivity of an individual tumor to
chemotherapy in the context of different histological and
pathological variables. This is in particular helpful since
breast cancer is increasingly recognized as a heterogeneous
disease and the need for individualized therapy is widely
accepted. Major biological and clinical differences exist
between the two most common histological subtypes;
invasive ductal carcinoma and invasive lobular carcinoma.
Invasive ductal carcinoma is the most common type of
breast cancer and originates from the milk ducts. Invasive
lobular carcinoma starting in the milk-producing lobules is
characterized by a diffuse grown pattern (the so-called
Indian-ﬁle pattern) and the loss of E-cadherine expression
(a glycoprotein that mediates adhesion between epithelial
cells). Lobular carcinoma is more frequently positive for
the estrogen receptor than ductal carcinoma. At presenta-
tion, patients with lobular disease are typically older and
their tumors tend to be larger in size. Unfortunately, almost
none of the randomized trial assessing chemosensitivity in
the adjuvant or the neoadjuvant setting report the effec-
tiveness of chemotherapy separately for patients with
lobular carcinoma.
6 Six retrospective case series of neo-
adjuvant chemotherapy showed a pathological complete
response (pCR) rate in lobular carcinoma of 1.7% (6 of
354) compared with 11.6% (300 of 2,584) in ductal car-
cinoma.
7–9 Despite the low pCR rate, patients with lobular
carcinoma had a higher survival compared with patients
with more chemosensitive ductal tumors.
8,9
Besides the histological subtypes, gene-expression pro-
ﬁling has led to the identiﬁcation of ﬁve different
molecular breast cancer subtypes (i.e., luminal A, luminal
B, basal and HER2 subtype, and normal-like subtypes).
10,11
To a degree, these molecular subtypes can be also be dis-
tinguished using immunohistochemistry.
12 Subtyping of
breast cancer by immunohistochemistry assays for estrogen
receptor (ER), progesterone receptor (PR), and human
epidermal growth factor 2 (HER2), yields three broad
groups: (1) ER-positive tumors, when ER is positive and
HER2 is not ampliﬁed; (2) triple-negative tumors when
ER, PR, and HER2 are all negative, and (3) HER2-positive
tumors, which may be ER-positive or ER-negative; The
molecular subtypes have been associated with prognosis.
The luminal A subtype has been shown to have a better
prognosis compared with the other subtypes and the basal
subgroup has the worst prognosis.
10,11,13 Comparably, tri-
ple-negative tumors have a worse prognosis than ER-
positive tumors.
14 Research increasingly suggests that the
molecular subtypes are associated with chemosensitivity.
The basal and triple-negative subtypes has been shown to
be more sensitive to chemotherapy than the luminal and
ER-positive breast cancer.
15–18
The aim of this manuscript was to analyze differences in
the outcome of neoadjuvant chemotherapy between both
histological and receptor-based subtypes. Primary outcome
measures were the increase in breast-conserving therapy
and pathological complete remission.
METHODS
Patients
A consecutive series of 254 patients with primary
operable breast tumors who received neoadjuvant chemo-
therapy between January 2000 and April 2007 were
retrospectively analyzed. In our institute, patients with
invasive breast cancer greater than 3 cm and/or involved
lymph nodes are typically eligible for treatment within a
neoadjuvant chemotherapy protocol. Patients with inoper-
able breast tumors (T4 and/or N3) were excluded from this
analysis. Patients received neoadjuvant chemotherapy in 1
of 2 clinical studies ongoing or received treatment
according to the standard arm of these trials.
19 The clinical
studies were approved by the institutional ethical com-
mittee and informed consent was obtained from all
patients.
The tumor size was assessed with ultrasound, mam-
mography, and contrast-enhanced MRI.
Nodal status prior to neoadjuvant chemotherapy was
determined by ultrasound-guided ﬁne-needle aspiration or,
when negative, sentinel node biopsy. Prior to neoadjuvant
treatment, 14-gauge biopsies of the breast tumor were
taken under ultrasound guidance to determine the histo-
logical subtype, hormone receptor, and HER2-status. In the
majority of patients a marker was placed in the tumor for
surgical detection and for optimal pathological examina-
tion of the tumor area in the surgical specimen after
neoadjuvant chemotherapy.
Chemotherapy Regimens
Since the year 2000, patients could participate in a study
randomizing patients between AC (6 cycles of doxorubicin
60 mg/m
2 and cyclophosphamide 600 mg/m
2, every
3 weeks) and AD (6 cycles of doxorubicin 50 mg/m
2 and
docetaxel 75 mg/m
2). A total of 107 patients were treated
in this period; 51 participated in the trial, and 56 were
2412 M. E. Straver et al.treated according to the standard arm (AC). In 2005 this
trial was followed by a new neoadjuvant trial. In this trial
the treatment regimen depended on the presence or
absence of HER2 ampliﬁcation. Furthermore, the tumor
response was evaluated by contrast-enhanced MRI and
clinical examination after 1 or 3 cycles (depending on the
speciﬁc regimen).
4 Chemotherapy regimens were changed
to a hypothetically non-cross-resistant regimen when
failure of response was apparent upon radiological eval-
uation. Preoperative chemotherapy for HER2-negative
tumors employed 1 of the following regimens: dose dense
(dd) AC (AC every 2 weeks with ﬁlgrastim) and/or DC (6
cycles of docetaxel 75 mg/m
2 and capecitabine 2 9 dd
1,000 mg/m
2 orally during 14 days, every 3 weeks).
20–22
For HER2-positive tumors, the regimens included PTC
(paclitaxel 80 mg/m
2/week, trastuzumab 2 mg/kg, and
carboplatin AUC 2 to 3 mg/ml per minute, given weekly
times 6, followed by 2 weeks trastuzumab alone, for 3
cycles). Of the 144 patients treated after 2005, 63 patients
participated in this trial and 81 patients were treated
according the standard arm of the protocol, with ddAC
chemotherapy.
Surgical and Adjuvant Treatment
The type of surgical treatment, breast-conserving
surgery or mastectomy, feasible at the time of diagnosis
was retrospectively assessed by an experienced breast
surgeon (MVP). The type of surgery feasible prior to
neoadjuvant chemotherapy was compared with the actual
surgery performed after neoadjuvant chemotherapy.
Recommendation for surgery was made by a multidis-
ciplinary team of breast cancer specialists including
surgeons, radiologists, pathologists, radiation, and medi-
cal oncologists. Treatment decisions were mainly based
on patient’s desires and surgical considerations involving
the breast-tumor index, age, multifocality, localization,
histology, and the presence of ductal invasive carcinoma
in situ (DCIS). All patients with proven axillary lymph
node metastases prior to neoadjuvant chemotherapy
underwent an axillary lymph node dissection (ALND) at
levels I and II with level III sampling after neoadjuvant
chemotherapy. Level III sampling was done to stage for
adjuvant radiotherapy indications.
23 Patients undergoing
breast-conserving surgery received radiation to the breast
with a boost to the tumor bed. The indication for loco-
regional radiation therapy (chest wall and regional nodal
basins) was based on the original staging. Hormone
receptor-positive patients received adjuvant endocrine
treatment for at least 5 years and HER2-positive patients
received trastuzumab for 1 year.
Pathological Examination
Tumors were classiﬁed according to the standard criteria
of the World Health Organization. Estrogen receptor (ER)
status and progesterone receptor status were determined by
immunohistochemistry and interpreted positive if more
than 10% of the nuclei stained positive. HER2 status was
assessed by scoring the intensity of membrane staining
using immunohistochemistry. Tumors with a score of 3?
(strong homogeneous staining) were considered HER2-
positive. In case of 2? scores (moderate homogeneous
staining) chromogenic in situ hybridization (CISH) was
used to determine ampliﬁcation. The tumor margins were
deﬁned as a clear pathologic margin if the distance was
[2 mm on microscopic evaluation. Pathological complete
response (pCR) was deﬁned as the absence of invasive
carcinoma in both the breast and axilla at microscopic
examination of the resection specimen, regardless of the
presence of carcinoma in situ.
24
Statistical Analysis
Analyses were performed using SPSS version 15.1
(SPSS Inc, Chicago, IL) and SAS version 9.1 (SAS Insti-
tute Inc. Cary, NC, VS) Differences in clinical data were
tested using the v
2 or Fisher exact test where appropriate. A
multivariate logistic regression model was built to examine
the associations between pCR and age, menopausal status,
tumor stage (T1 vs. T2 vs. T3), N stage (N0 vs. N1),
molecular subtype based on tumor receptor status (ER-
positive vs. triple-negative vsHER2-positive), histology
(ductal vs. lobular vs. other). The level of signiﬁcance was
set at 0.05.
RESULTS
Table 1 shows the patient and tumor characteristics. The
median age was 45 years (range 23–76), and the majority
of patients were premenopausal (70%) and had ductal
carcinomas (78%). Also, 70% of the patients were treated
with an antracycline-based regimen (AC), 20% with a
taxane-based regimen (AD or CD), and 8% received
trastuzumab in combination with chemotherapy (PTC).
Increase in Breast-Conserving Surgery
After neoadjuvant chemotherapy, 251 of 254 patients
received surgery to the breast; three patients refused
additional surgical treatment. Before the administration of
neoadjuvant chemotherapy, 53 patients could be treated
with breast-conserving therapy whereas mastectomy was
indicated in the remaining 198 patients. After neoadjuvant
Neoadjuvant Chemotherapy in Operable Breast Cancer 2413chemotherapy, breast-conserving surgery was possible in
an additional 73 patients. Thus, the increase in breast-
conserving surgery was 37% (73 of 198). None of the 53
patients, in whom breast-conserving surgery was feasible
prior to neoadjuvant chemotherapy, had to undergo a
mastectomy after neoadjuvant chemotherapy because of
progressive disease.
The tumor margin was not clear after breast conserving
therapy (including carcinoma in situ) in 32 of 135 patients
(24%). In 21 patients no re-excision or subsequent mas-
tectomy was done because the tumor was only marginally
incomplete excised. These patients were treated with
adjuvant radiotherapy. Two patients were treated with a re-
excision. In nine patients, the incomplete resection margins
led to a subsequent mastectomy, due to more than focally
involved margins, and no room for further local resections
to achieve a cosmetically acceptable outcome.
After a median follow up of 35 months (range, 5–101),
eight patients (3%, 8 of 251) had a local recurrence. The
local recurrence rate was similar in the group of patients
that were switched to breast-conserving surgery (3%, 2 of
73). The median overall survival and disease-free survival
were 90% (95% conﬁdence interval [95% CI] 86%–94%)
and 86% (95% CI 82%–91%), respectively.
Figure 1 shows the ﬁndings at surgery separately for
ductal and lobular carcinomas. Of the patients with ductal
carcinomas (n = 195), 152 patients initially had an indi-
cation for mastectomy. After neoadjuvant chemotherapy,
65 patients underwent breast-conserving surgery. Two
patients had incomplete resection margins, leading to a
subsequent mastectomy. Thus, the increase in breast con-
serving surgery was 41% (63 of 152). Of the patients with
lobular carcinomas (n = 42), 35 patients initially had an
indication for mastectomy; 14 of these patients underwent
breast-conserving surgery after neoadjuvant chemotherapy.
Unfortunately, 7 of the 14 patients (50%) had to subse-
quently undergo a mastectomy due to incomplete resection
margins. The increase in breast-conserving surgery in
lobular carcinoma was 20% (7 of 35) and was signiﬁcantly
lower than in ductal carcinoma (P = 0.02).
Figure 2 shows the ﬁndings at surgery separately for the
different subtypes based on receptor status. Of the patients
with ER-positive tumors (n = 138), 109 patients initially
had an indication for mastectomy. After neoadjuvant che-
motherapy 50 patients underwent breast-conserving
surgery. Eight patients (16%) had incomplete resection
margins leading to a subsequent mastectomy. Thus, the
increase in breast-conserving surgery was 39% (42 of 109).
Remarkably, seven of the eight patients in the ER-positive
group with incomplete resection margins leading to a
secondary mastectomy had a lobular carcinoma.
Of the patients with triple-negative tumors (n = 57), 45
patients initially had an indication for mastectomy. The
increase in breast-conserving surgery was 24% (11 of 45),
and none of the patients had incomplete resection margins
leading to a secondary mastectomy. In the patients with
HER2-positive tumors (n = 56) a mastectomy was indi-
cated before neoadjuvant chemotherapy in 44 patients. The
TABLE 1 Patient and tumor characteristics
No. %
Total number of patients 254
Median age (range) 45 (23–76)
Menopausal status
Premenopausal 179 70
Perimenopausal 8 3
Postmenopausal 59 23
Unknown 8 4
T-stage
T1 13 5
T2 151 59
T3 90 35
N-stage
N0 (SNB
–)4 3 1 7
N1 (FNA
?/SNB
?) 170 67
NX 41 16
Histology
Ductal 197 78
Lobular 37 15
Mixed 6 2
Adenocarcinoma (NS) 14 5
Receptor-based subtype
ER-positive (ER
?; HER2
–) 140 55
Triple-negative (ER
–;P R
–; HER2
–)5 8 2 3
HER2
? 56 22
Participating in trial
Study 1(before 2005, without switch) 51 20
Without randomization 56 22
Study 2(after 2005, with switch) 63 45
Without randomization 81 32
Other 3 1
Chemotherapy regimen
Doxorubicin–cyclophosphamide (AC) 178 70
Capecitabine–docetaxel (CD) 24 10
Paclitaxel–trastuzumab–carboplatin (PTC) 20 8
Doxorubicin–docetaxel (AD) 26 10
Other 6 2
Surgery
Yes 25 98
No 2 1
Axillary lymph node dissection only 1 1
SNB sentinel node biopsy, FNA ﬁne needle aspiration, ER estrogen-
receptor, PR progesterone receptor, HER2 human epidermal growth
factor receptor 2, NS not speciﬁed
2414 M. E. Straver et al.increase in breast-conserving surgery was 45% (20 of 44),
and in one patient (5%) a secondary mastectomy was
performed due to incomplete resection margins. The
increase in breast-conserving surgery was not signiﬁcantly
different between the receptor based subtypes (P = 0.11).
Pathological Complete Response (pCR) Rates
Overall, 12% (29 of 251) of the patients who had sur-
gery after neoadjuvant chemotherapy achieved a pCR of
both the primary tumor and lymph node metastases. A
complete remission of only the primary tumor in the breast
was seen in 18% (45 of 251) (Table 2). The axillary pCR
rate was calculated from the group of patients with proven
lymph node metastases prior to neoadjuvant chemotherapy,
in whom the positive lymph nodes were left in situ. Thus,
the patients with a positive sentinel node biopsy prior to
neoadjuvant chemotherapy were excluded (n = 24). The
axillary pCR rate was 16% (23 of 146) in this group of
patients.
Patients with ductal carcinoma had a higher pCR rate
compared with patients with lobular carcinoma, 12% (23 of
195) vs. 2% (1 of 42), respectively (P = 0.09). Based on
the receptor status, the pCR rate in ER-positive, triple-
negative, and HER2-positive tumors was 2% (3 of 138),
28% (16 of 57), and 18% (10 of 56), respectively
(P\0.001). HER2-positive patients treated with trast-
uzumab and chemotherapy achieved a pCR in 35% (7 of
Lobular
(n = 42)
Ductal
(n = 195)
Total
Histology
Surgery Feasible
Prior to NAC
Surgery
Performed
after NAC
Secondary
Surgery
Final Surgery
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after Median 35
Months (5–101)
n = 251
Other
(n = 14)
BCS
(n = 7)
BCS
(n = 7)
BCS
(n = 7)
n = 0
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(n = 14)
BCS (n = 7)
7/35 = 20%
n = 0
(0/7 = 0%)
Mastectomy
(n = 21)
Mastectomy
(n = 28)
n = 2
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63/152 = 41%
n = 2
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Mastectomy
(n = 87)
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n = 2
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(n = 2) 3%
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(n = 152)
FIG. 1 Increase in breast-
conserving surgery by
histological subtype. The type of
surgery feasible prior to
neoadjuvant chemotherapy is
compared with the actual surgery
performed after neoadjuvant
chemotherapy. The increase in
breast-conserving surgery (shown
in the blue boxes) is higher in
ductal carcinomas. NAC,
neoadjuvant chemotherapy; BCS,
breast-conserving surgery
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FIG. 2 Increase in breast-
conserving surgery by receptor-
based subtype. The type of
surgery feasible prior to
neoadjuvant chemotherapy is
compared with the actual surgery
performed after neoadjuvant
chemotherapy. The increase in
breast-conserving surgery (shown
in the blue boxes) is highest in
HER2-positive carcinomas.
NAC, neoadjuvant
chemotherapy; BCS, breast
conserving surgery
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(P = 0.025). Additionally, we assessed variables that were
predictive for a pCR in a multivariate analysis. Among the
variables age, menopausal status, tumor stage, N stage, and
histology, the receptor-based subtype was the only signif-
icant predictor of pCR (P = 0.004), with triple-negative
patients being more chemosensitive (odds ratio 14.8, 95%
CI 2.79–78.4) than ER-positive tumors. With regard to the
response of the primary tumor regardless of the axillary
response, multivariate analysis showed that both T-stage
(P = 0.006) and receptor-based subtype (P = 0.002) sig-
niﬁcantly predicted a complete remission.
DISCUSSION
In this study, we assessed the outcome of neoadjuvant
chemotherapy in different breast cancer subtypes in a
consecutive series of 254 patients with operable breast
cancer.
In lobular carcinomas, the pathological response rate as
well as the increase in breast conserving was relatively
low, 2% and 20%, respectively. Moreover, in half of the
patients a secondary mastectomy had to be performed due
to incomplete resection margins. This might be explained
by the difﬁculty of determining the size of residual disease
after neoadjuvant chemotherapy in lobular carcinoma
patients even when using contrast enhanced MRI.
25,26
Their unique linear and scattered growth pattern may
account for these problems. Reducing the vascularity might
appear as a decrease in tumor size on MRI, while it does
not inﬂuence the malignant cells growing single ﬁle,
resulting in underestimation of the tumor size. Further
research focusing on the imaging of lobular carcinomas
after neoadjuvant chemotherapy is warranted. Based on our
results we recommend informing patients with lobular
disease about the risk on a secondary mastectomy and to be
cautious in offering these patients breast-conserving sur-
gery after neoadjuvant chemotherapy. Moreover, the
problem in surgical treatment suggests that the majority of
patients with lobular breast cancer have no clinical beneﬁt
of neoadjuvant treatment above adjuvant chemotherapy.
Therefore, it might be argued that direct surgical treatment
should be considered outside clinical studies. Several
studies examining the differences between lobular and
ductal carcinomas show a low pCR rate of 0–3% in patients
with lobular carcinomas.
6,9,27 The only patient with a
lobular carcinoma achieving a pCR in our series had a
HER2-positive tumor and was treated with trastuzumab
and chemotherapy. This ﬁnding suggests that receptor-
status is very predictive for chemosensitivity. In addition,
this study shows that the receptor-based subtype was the
only variable signiﬁcantly associated with pCR in the
multivariate analysis. ER-positive tumors had lower pCR
rate compared with triple-negative and HER2-positive
breast cancer. Carey et al. observed similar results when
classifying patients in molecular subgroups according to
immunohistochemical staining.
15 Remarkably, the increase
in breast-conserving surgery was high in ER-positive
ductal tumors (39%), which implies that the tumor load
reduces signiﬁcantly. This ﬁnding suggests that treatment
with neoadjuvant chemotherapy does have a clinical ben-
eﬁt in a large number of patients with ER-positive disease
(39%). It is questionable whether pathological complete
response is the best surrogate marker for the chemosensi-
tivity in estrogen receptor-positive breast cancer. The low
incidence of pCR hampers research to predictive factors of
chemosensitivity and the comparison of different treatment
regimens in the relatively large group of estrogen receptor-
positive disease.
28 Recently a new surrogate, the residual
cancer burden (RCB), has been proposed to measure
chemosensitivity as a continuous variable derived from the
primary tumor dimensions, cellularity of the tumor bed,
and axillary nodal burden.
29 RCB was a signiﬁcant pre-
dictor of distant relapse-free survival and can be used to
more precisely determine the chemosensitivity.
HER2-positive patients showed a both a high pCR rate
(18%) as well as a signiﬁcant increase in breast-conserving
surgery (45%). HER2 ampliﬁcation is observed in 15–25%
of the patients with breast cancer, especially in ductal
carcinomas. The beneﬁt of adding trastuzumab to neoad-
juvant regimens, as seen in this report, has been proven in a
randomized trial showing a pCR rate of 65% in HER2-
positive patients treated chemotherapy combined with
trastuzumab compared to a pCR rate of 26% in patients
treated with chemotherapy only.
30 In our study we
TABLE 2 Pathological response according to histological and
molecular subtype
No. pCR breast
and axilla
pCR
breast
No. (%) No. (%)
Histological subtype
Ductal 195 23 (12) 36 (18)
Lobular 42 1 (2) 1 (2)
Adenocarcinoma (NS) 14 5 (36) 8 (57)
Receptor-based subtype
ER-positive
(HER2-negative)
138 3 (2) 9 (7)
Triple-negative 57 16 (28) 20 (35)
HER2? 36 3 (8) 5 (14)
HER2?T 20 7 (35) 11 (55)
Total 251 29 (12) 45 (18)
pCR pathological complete remission, ER estrogen receptor, HER2
human epidermal growth factor receptor 2, Triple-negative ER and
progesterone receptor (PR) and HER2-negative (triple negative),
HER2?T HER2-positive and treated with trastuzumab
2416 M. E. Straver et al.classiﬁed all HER2-positive tumors into 1 subgroup.
However, HER2-positive tumors that are ER-positive are
less chemosensitive than HER2-positive tumors that are
ER-negative. In this report we did not subdivide the HER2-
positive patients because of the small sample size and
different treatment regimens within this subgroup.
Triple-negative tumors showed a high pCR rate (28%)
and a slightly lower increase in breast conserving surgery
(24%) compared with the other subtypes. This might be
explained by the high incidence of BRCA carriers (7 of 58
patients in this series) and young patients, in which a
mastectomy is preferably performed or desired.
The overall increase in breast-conserving surgery
assessed in our patient population with operable breast
cancer was high and the local recurrence is low after a
median follow-up of 34 months. Several aspects might
have contributed to this high success rate. Firstly,
marking of the primary tumor prior to neoadjuvant
chemotherapy is important. After neoadjuvant chemo-
therapy, many of the tumors may become nonpalpable
and difﬁcult to visualize by imaging modalities. The
marker can be used to localize the tumor before surgery
and assists the pathologist in detecting the tumor-bearing
area. Secondly, evaluation of the residual disease with
contrast enhanced MRI is superior to conventional
methods.
31,32 The ability of MRI to distinguish ﬁbrous
from vascularized tissue after the administration of
contrast medium underlies this advantage. However, the
negative predictive value of MRI is low.
25 Therefore, we
never omit surgical treatment in complete responders
assessed at MRI.
In conclusion, this study shows that it is essential to
obtain information about the histology and the hormone
and HER2 receptor status before the administration of
neoadjuvant chemotherapy. Patients with lobular carcino-
mas should be well informed about the low probability of
having a pCR and breast-conserving surgery with complete
resection margins after neoadjuvant chemotherapy.
Patients with estrogen receptor positive disease have a low
likelihood of achieving a pCR; however, the increase in
breast-conserving therapy is remarkable in ductal carcino-
mas. Furthermore, the breast cancer subtype will become
increasingly important to determine the type of regimen as
currently applied in HER2-positive patients.
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